Associate Professor Michael Patrick Hay
BSc (Hons), PhD
Michael Hay obtained his BSc (Hons) and PhD in Chemistry from The University of Canterbury, New Zealand. After postdoctoral positions at Imperial College, London, and the University of Auckland, Michael was appointed as a Research Fellow in the Auckland Cancer Society Research Centre as a medicinal chemist in 1991. He is currently investigating bioreductive drugs that target the tumour microenvironment. He is an Associate Investigator in the Maurice Wilkins Centre for Molecular Biodiscovery.
Research | Current
Assoc. Prof. Hay has five principal Research Areas that together form a coherent body of work in the area of anti-cancer drug development selectively targeting the tumour microenvironment through bioreductive mechanisms and/or selective target inhibition. Secondary areas of interest include the development of novel drugs targeting M. tuberculosis, and new methodology in medicinal chemistry.
My current research interests are:
- Discovery of novel agents to target the tumour microenvironment
- Discovery of new hypoxia activated prodrugs
- Development of third generation nitroimidazole-based radiosensitizers
- Development of hypoxia activated prodrugs targeting DNA damage response pathways.
- Development of hypoxia-selective cytotoxins and radiation response modifiers based on the 1,2,4-benzotriazine dioxide core.
- Design and synthesis of drugs that target hypoxia-inducible factor (HIF-1alpha).
Selected publications and creative works (Research Outputs)
- Chernikova, S. B., Nguyen, R. B., Truong, J. T., Mello, S. S., Stafford, J. H., Hay, M. P., ... Henry, S. (2018). Dynamin impacts homology-directed repair and breast cancer response to chemotherapy. The Journal of clinical investigation, 128 (12), 5307-5321. 10.1172/JCI87191
- Hong, C. R., Dickson, B. D., Jaiswal, J. K., Pruijn, F. B., Hunter, F. W., Hay, M. P., ... Wilson, W. R. (2018). Cellular pharmacology of evofosfamide (TH-302): A critical re-evaluation of its bystander effects. Biochemical pharmacology, 156, 265-280. 10.1016/j.bcp.2018.08.027
Other University of Auckland co-authors: Benjamin Dickson, Jagdish Jaiswal, Frederik Pruijn, Francis Hunter, Kevin Hicks, William Wilson, Cho Rong Hong
- Bonnet, M., Hong, C. R., Wong, W. W., Liew, L. P., Shome, A., Wang, J., ... Anderson, R. F. (2018). Next-generation hypoxic cell radiosensitizers: Nitroimidazole alkylsulfonamides. Journal of Medicinal Chemistry, 61 (3), 1241-1254. 10.1021/acs.jmedchem.7b01678
Other University of Auckland co-authors: Lydia Liew, Way Wong, Bob Anderson, Stephen Jamieson, Kevin Hicks, Frederik Pruijn, Yongchuan Gu, Ralph Stevenson, William Wilson, Avik Shome, Cho Rong Hong
- Gu, Y., Chang, T. T.-A., Wang, J., Jaiswal, J. K., Edwards, D., Downes, N. J., ... Hickey, A. J. (2017). Reductive metabolism influences the toxicity and pharmacokinetics of the hypoxia-targeted benzotriazine di-oxide anticancer agent SN30000 in mice. Frontiers in Pharmacology, 8, 1-16. 10.3389/fphar.2017.00531
Other University of Auckland co-authors: Tony Hickey, Yongchuan Gu, Jagdish Jaiswal, Frederik Pruijn, William Wilson, Kevin Hicks, Courtney Lynch
- Yuan, W., Jiang, D., Nambiar, D., Liew, L., Hay, M., Bloomstein, J., ... Tibshirani, R. (2017). Chemical space mimicry for drug discovery. Journal of Chemical Information and Modeling, 57 (4), 875-882. 10.1021/acs.jcim.6b00754
Other University of Auckland co-authors: Lydia Liew
- Hay, M. P., Hicks, K. O., & Wilson, W. R. (2017). Discovery of the hypoxia-activated prodrug SN30000. In S. Chackalamannil, D. Rotella, S. Ward (Eds.) Comprehensive medicinal chemistry III. Volume 8, Case histories in recent drug discovery (pp. 58-94). Oxford, UK: Elsevier. 10.1016/B978-0-12-409547-2.12450-3
Other University of Auckland co-authors: Kevin Hicks, William Wilson
- Jiang, D., Tam, A. B., Alagappan, M., Hay, M. P., Gupta, A., Kozak, M. M., ... Giaccia, A. J. (2016). Acridine derivatives as inhibitors of the IRE1α-XBP1 pathway are cytotoxic to human multiple myeloma. Molecular Cancer Therapeutics, 15 (9), 2055-2065. 10.1158/1535-7163.MCT-15-1023
- Anderson, R. F., Yadav, P., Shinde, S. S., Hong, C. R., Pullen, S. M., Reynisson, J., ... Hay, M. P. (2016). Radical chemistry and cytotoxicity of bioreductive 3-substituted quinoxaline Di-N-oxides. Chemical Research in Toxicology, 29 (8), 1310-1324. 10.1021/acs.chemrestox.6b00133
Other University of Auckland co-authors: Bob Anderson, William Wilson, Susan Pullen